Author: Editor

From the Myeloma 2018 meeting, held in San Diego, CA, the experts discuss novel targets in multiple myeloma (MM), including BRD4, Pykfvye and MCL1, and induced protein degradation, such as that via PROTAC. Faith Davies, MD, MRCP, MRCPath, of UAMS Myeloma Institute, Little Rock, AR, chairs the discussion with Leif Bergsagel, MD, of the Mayo Clinic, Phoenix, AZ, Robert Orlowski, MD, PhD, of the MD Anderson Cancer Center, Houston, TX, and Keith Stewart, MB, ChB, of the Mayo Clinic. Dr Bergsagel discussed the already known targets in MM which still do not have a drugs specific for them. Dr Stewart…

The progression to multiple myeloma (MM) in patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) needs to be understood in order to prevent and manage the condition to the best of our ability. Topical themes covered by the experts in this panel discussion include whether we are ready to treat SMM outside of trials, new mouse models of progression, the role of the immune system in this disease transition, and epigenetic modifications in MM. At the Myeloma 2018 meeting in San Diego, CA, Larry Boise, PhD, of Emory University School of Medicine, Atlanta, GA, chairs…

In this exciting discussion, the experts explore the prevocative question of ‘is precision medicine a bust in multiple myeloma?’ Topics discussed include the limitations and future potential of precision medicine, the impact of 1q copy number on prognosis and the level of BRAF mutation needed for response to inhibitors. Rafael Fonesca, MD, of the Mayo Clinic, Phoenix, AZ, chairs this discussion with Dirk Hose, MD, of University Hospital Heidelberg, Heidelberg, Germany, Faith Davies, MD, MRCP, MRCPath, FRCPath, of UAMS Myeloma Institute, Little Rock, AR, and Jeffrey Wolf, MD, of UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, at…

From the Myeloma 2018 meeting, held in San Diego, CA, Gareth Morgan, MD, PhD, FRCP, FRCPath, of UAMS Myeloma Institute, Little Rock, AR, chairs a discussion with Jens Lohr, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, Angela Dispenzieri, MD, of the Mayo Clinic, Rochester, MN, Ola Landgren, MD, PhD, of the Memorial Sloan Kettering Cancer Center, New York, NY. The experts discuss a range of topics including advanced methods of detecting and monitoring measurable residual disease (MRD), such as single cell RNA sequencing, protein-based detection in the peripheral blood using mass spectrometry, and the highly sensitive VDJ sequencing.

Keith Stewart, MB, ChB from the Mayo Clinic, Rochester, MN, is joined by Kenneth Anderson, MD, of the Dana-Farber Cancer Institute, Boston, MA, and Sagar Lonial, MD, of the Winship Cancer Institute of Emory University, Atlanta, GA, to share their highlights from day 1 of the Myeloma 2018 meeting, held in San Diego, CA. Hear their thoughts on precision medicine, immunotherapy, genomics, epigenetics, novel agents and more.

CAR T-cells are an exciting new therapeutic area in multiple myeloma (MM). Here, the experts discuss the current landscape of this novel therapy in MM, including exploratory targets; with not all convinced that BCMA is the optimal target. Furthermore, the cost vs. value of CAR T-cell therapy is explored, with several types of payment systems proposed. Chaired by David Siegel, MD, PhD, of the John Theurer Cancer Center, Hackensac, NJ, the dicussion includes Andrew Spencer, MBBS, FRACP, FRCPA, DM, of Alfred Hospital, Monash University, Melbourne, Australia, and Ravi Vij, MD, MBA, of Washington University Medical School, St. Louis, MO. This…

CRISPR technology is being used to define mechanisms of multiple myeloma (MM) drug resistance. Here, Constantine Mitsiades, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, discusses his group’s work in this exciting area, investigating Cereblon pathway-mediated resistance to thalidomide and its derivatives, lenalidomide and pomalidomide. He concludes by highlighting what can be done in future trials to select patients who do not have this resistance. This interview took place at the Myeloma 2018 meeting, held in San Diego, CA.

Treatment of advanced Hodgkin lymphoma has evolved dramatically in the last 10 years, especially with the introduction of PET-response adapted treatment and the introduction of novel agents. Martin Hutchings, MD, PhD from the Copenhagen University Hospital, Copenhagen, Denmark discusses the latest advances and how they have changed the way we treat advanced Hodgkin lymphoma. This video was recorded at the EBMT 2018 Annual Meeting, held in Lisbon, Portugal.

Florent Malard, MD, PhD, of Saint Antoine Hospital, Paris, France, discusses potential measures to improve the outcome of transplantation at the 2018 European Group for Blood and Marrow Transplantation (EMBT) Annual Meeting, held in Lisbon, Portugal. He emphasizes the need for further research into the impact of NKT cells on the complications of transplantation, namely graft-versus-host disease (GvHD). Dr Malard also discusses his teams analysis comparing the use of anti-thymocite globulin (ATG)-based in vivo depletion and CD34 selected grafts with ex vivo depletion in patients with acute myeloid leukemia (AML) with GvHD.

Here, Steven Pavletic, MD, MS, from the National Cancer Institute, Bethesda, MD, outlines areas of improvement for treating chronic graft-versus-host disease (GvHD), the future therapeutic landscape, and encourages patient enrollment in clinical trials to help further knowledge. Dr Pavletic was speaking from the European Society for Blood and Marrow Transplantation (EBMT) 2018 Annual Meeting, held in Lisbon, Portugal.

Here, Steven Pavletic, MD, MS, from the National Cancer Institute, Bethesda, MD, outlines areas of improvement for treating chronic graft-versus-host disease (GvHD), the future therapeutic landscape, and encourages patient enrollment in clinical trials to help further knowledge. Dr Pavletic was speaking from the European Society for Blood and Marrow Transplantation (EBMT) 2018 Annual Meeting, held in Lisbon, Portugal.

By understanding the pathogenesis of chronic graft-versus-host disease (GvHD), treatments can be better targeted to improve patient outcomes. In this video, Steven Pavletic, MD, MS, from the National Cancer Institute, Bethesda, MD, talks about targeting T-cell, B-cell and APC activation to treat chronic GvHD, in order to derive alternative therapies to corticosteroid treatment. Dr Pavletic was speaking from the European Society for Blood and Marrow Transplantation (EBMT) 2018 Annual Meeting, held in Lisbon, Portugal.

By understanding the pathogenesis of chronic graft-versus-host disease (GvHD), treatments can be better targeted to improve patient outcomes. In this video, Steven Pavletic, MD, MS, from the National Cancer Institute, Bethesda, MD, talks about targeting T-cell, B-cell and APC activation to treat chronic GvHD, in order to derive alternative therapies to corticosteroid treatment. Dr Pavletic was speaking from the European Society for Blood and Marrow Transplantation (EBMT) 2018 Annual Meeting, held in Lisbon, Portugal.

Here, Steven Pavletic, MD, MS, from the National Cancer Institute, Bethesda, MD, discusses the previous management of chronic graft-versus-host disease (GvHD), with the BTK inhibitor ibrutinib having been approved for the treatment of patients with chronic GvHD. From the European Society for Blood and Marrow Transplantation (EBMT) 2018 Annual Meeting, held in Lisbon, Portugal, Dr Pavletic also outlines the biology of the disease and how its understanding has been improved significantly with recently conducted research.

In this video, Steven Pavletic, MD, MS, from the National Cancer Institute, Bethesda, MD, speaks at the European Society for Blood and Marrow Transplantation (EBMT) 2018 Annual Meeting, held in Lisbon, Portugal, and outlines the salvage therapy options for steroid-refractory chronic graft-versus-host disease (GvHD).

From the European Society for Blood and Marrow Transplantation (EBMT) 2018 Annual Meeting, held in Lisbon, Portugal, Steven Pavletic, MD, MS, from the National Cancer Institute, Bethesda, MD, discusses the diagnostic approach for chronic graft-versus-host disease (GvHD).

Steven Pavletic, MD, MS, from the National Cancer Institute, Bethesda, MD, gives an overview of the management of chronic graft-versus-host disease (GvHD) from the European Society for Blood and Marrow Transplantation (EBMT) 2018 Annual Meeting, held in Lisbon, Portugal.

Treating aplastic anemia (AA) with transplantation in a pediatric population is deemed relatively complicated, according to Régis Peffault de Latour, MD, PhD, of Saint Louis Hospital, Paris, France. He states that in children with no siblings, the toxicity levels for transplantation of an unrelated match is low. He highlights how a lack of immunosuppression before transplantation could be beneficial for patients under the age of 20, as they will not experience prolonged neutropenia. Dr Peffault de Latour also mentions that for older patients suffering from AA, treatments such as cyclosporin are preferred over transplantation due to toxicity. He also explains…

Régis Peffault de Latour, MD, PhD, from Saint Louis Hospital, Paris, France, discusses the main challenges in managing patients with idiopathic aplastic anemia. He identifies three key challenges, including the place of receptor agonists, transplantation in elderly patients, and upfront match-unrelated transplantation in the pediatric population. Dr Peffault de Latour highlights the numerous studies being conducted worldwide in order to overcome the transplantation problems in these populations. This interview was recorded at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal.

From the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting, held in Lisbon, Portugal, Régis Peffault de Latour, MD, PhD, of Saint Louis Hospital, Paris, France, discusses the treatments currently available for treating paroxysmal nocturnal hemoglobinuria (PNH). He states how classic PNH can be treated effectively with complement blockers, thus transplant tends to not be an option. However, with PNH associated with aplastic anemia, transplantation is the only curative treatment available with minimal toxicities and a successful outcome.

Speaking from the 2018 European Group for Blood and Marrow Transplantation (EBMT) Annual Meeting, held in Lisbon, Portugal, Fermin Sanchez-Guijo, MD, PhD, of the Hospital Clínico Universitario de Salamanca, Salmanca, Spain, speaks to us about the Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and the EBMT – JACIE. As March 2018 marked the 20th anniversary of this committee, Dr Sanchez-Guijo highlights the important work of JACIE, particularly with an array of new cellular therapy options.

In this interview, recorded at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Andrés Ferreri, MD, of IRCCS San Raffaele Hospital, Milan, Italy, outlines the difficulties of treating double-hit lymphoma, a rare but aggressive disease.

Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Andrés Ferreri, MD, of IRCCS San Raffaele Hospital, Milan, Italy, describes the difficulties associated with treating high-risk patients with diffuse large B-cell lymphoma (DLBCL).

Dividing patients into subgroups for different therapies can often be quite difficult. In this interview, recorded at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Andrés Ferreri, MD, of IRCCS San Raffaele Hospital, Milan, Italy, outlines the difficulties that still exist today with regards to classifying patients as high-risk, and mentions improvements that must be made in geriatric cases to improve the efficacy of treatment in the elderly.

Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Abdul Hamid Bazarbachi, from the American University of Beirut, Beirut, Lebanon, discusses the key topics from the conference and highlights his top picks.

In this video, Andrew Armstrong, MD, from Duke University, Durham, NC, talks about the potential of the PROSPER (NCT02003924) and SPARTAN (NCT01946204) Phase III trials for nonmetastatic castration-resistant prostate cancer. From the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Dr Armstrong points to limitations with current therapy, and how research into osteomimicry can help develop treatments that aim to cure bone metastases in these patients, rather than merely delaying the symptoms.

From the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Andrew Armstrong, MD, from Duke University, Durham, NC, highlights the need for novel therapies targeting plasticity pathways in particular, in order to treat bone metastases in patients with prostate cancer. Dr Armstrong also outlines potential predictive biomarkers, including DNA defects in PARP inhibitors and androgen receptor defects.

Bone metastases are present in the majority of patients with prostate cancer and are the main cause of mortality in these patients. Here, Andrew Armstrong, MD, from Duke University, Durham, NC, discusses the role of osteomimicry in the formation of bone metastases, and the challenges concerning their treatment. From the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Dr Armstrong outlines potential research pathways for exploration.

Speaking from the 2018 Genitourinary Cancers Symposium in San Francisco, CA, Peter Black, MD, of the University of British Columbia, Vancouver, CA, outlines the development of systemic therapy for non-muscle invasive bladder cancer.

From the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Elizabeth Plimack, MD, from Fox Chase Cancer Center, Philadelphia, PA, introduces the key trials in progress at her center, including a treatment allocation study for patients with muscle-invasive localized bladder cancer, which features a combination of cystoscopy and tumour genomics to reduce the number of patients undergoing cystectomy. In addition, Dr Plimack also highlights a trial testing the combination of nivolumab and axitinib for kidney cancer (NCT03172754). Finally, she discusses a study looking to sensitize bladder cancer patients that are refractory to PD-1 inhibiton using guadecitabine (NCT03179943).

Here, Francesco Montorsi, MD, from Vita-Salute San Raffaele University, Milan, Italy, speaks at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, about how the outcome of patients with renal cell carcinoma (RCC) could potentially be improved, with promising emerging data on novel therapies. Prof. Montorsi speaks about his experience as a physician, and how both patients with localized renal cancer and those with aggressive disease tend to have a poor prognosis, which highlights the need for novel drug studies that could improve patient outcomes. Prof. Montorsi concludes that drugs which target the immune system have been particularly effective…

Speaking from the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Michael Atkins, MD, of Georgetown University, Washington, DC, outlines the changing landscape of kidney cancer, explaining the therapies at the forefront of the field right now. Dr Atkins highlights immuno-oncology combinations, mentioning a number of checkpoint inhibitors and VEGF inhibitors, including ipilimumab, nivolumab, atezolizumab, bevacizumab, cabozantinib, lenvatinib, everolimus, axitinib, avelumab, and sunitinib.

At the Genitourinary Cancers Symposium 2018 in San Francisco, CA, recent therapeutic developments for renal cell carcinoma (RCC) were discussed by Jeanny Aragon-Ching, MD, FACP, of Inova Schar Cancer Institute, Falls Church, VA. She spoke about the changes in practice and therapy, highlighting the rise of systemic therapies such as VEGF inhibitors. Dr Aragon-Ching explains how immunotherapy has always been a second-line treatment; however, with the results of recent trials, these therapies are seen as being increasingly effective. For example, the IMmotion151 randomized Phase III study of bevacizumab and atezolizumab vs. sunitinib for metastatic RCC (NCT02420821). Dr Aragon-Ching also mentions…

Dr. Jack West describes an emerging theme that the best outcomes for patients with lung cancer and likely other cancer are best served by receiving the best agents up front, a strategy that implies a value in integrating more treatments into early combos.

BCG immunotherapy is one of the primary treatment options for bladder cancer patients who are ineligible for cystectomy. However, some patients continue to have persistant high-grade disease long after treatment, prompting the development of new drugs such as atezolizumab. In this video, Peter Black, MD, of the University of British Colombia, Vancouver, Canada, discusses a clinical trial investigating the efficacy of atezolizumab in BCG-unresponsive bladder cancer (NCT02844816). This interview took place at the 2018 Genitourinary Cancers Symposium in San Francisco, CA.

Michael Atkins, MD, of Georgetown University, Washington DC, outlines the results of the study of VEGF inhibitor axitinib in combination with pembrolizumab for the first-line treatment of advanced renal cell cancer (NCT02133742). Dr Atkins goes onto explain the next steps required for this result to impact treatment, and eagerly awaits the results of the KEYNOTE-426 trial (NCT02853331). This interview took place at the 2018 Genitourinary Cancers Symposium in San Francisco, CA.

Elizabeth Plimack, MD, from Fox Chase Cancer Center, Philadelphia, PA, gives an overview of a study (NCT02133742) looking at pembrolizumab combined with axitinib for the first-line treatment of advanced kidney cancer. Speaking at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Dr Plimack hopes this combination can become the new frontline standard of care in renal oncology.

The use of prostate-specific antigen (PSA) levels as a diagnostic test for prostate cancer has significantly reduced mortality rates, as well as reducing the number of patients diagnosed with metastatic disease. In this video, Francesco Montorsi, MD, of Vita-Salute San Raffaele University, Milan, Italy, explains that even though PSA diagnostic tests have become a vital tool in diagnosing prostate cancer, there are still numerous patients whose cancers progress to metastatic status, or who have high PSA levels and metastatic disease at first consultation. Prof. Montorsi states that in these situations, there is currently no cure aside from delaying disease progression.…

Treatment for muscle-invasive bladder cancer has evolved as medical knowledge has expanded. Jeanny Aragon-Ching, MD, FACP, from Inova Schar Cancer Institue, Falls Church, VA, explains how, previously, the single treatment for muscle-invasive bladder cancer was a radical cystectomy, where patients still did not have the best outcomes. She talks about the need to incorporate a multidisciplinary approach, including medical oncologists, surgeons and radiation oncologists, in order to reach the most suitable treatment choice. Dr Aragon-Ching stresses how finding the right biomarkers is necessary to deliver the best care. She highlights how immunotherapy treatments for muscle-invasive cancer are still experimental, yet…

Speaking from the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Michael Atkins, MD, of Georgetown University, Washington, DC, tells us about the potential benefits of combining immunotherapy drugs with VEGF inhibitors such as axitinib in patients with renal cancer.

From the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Francesco Montorsi, MD, from Vita-Salute San Raffaele University, Milan, Italy, debates the benefits of abiraterone compared to standard chemotherapy for treating patients with prostate cancer. Prof. Montorsi also highlights unnecessary biopsies, and how these could potentially be avoided using fusion techniques. Prof. Montorsi mentions that patients should be involved in their own management plans, and that their preference of therapy should be taken into consideration. He urges healthcare professionals to regularly keep up to date on novel therapies and changes in practice to provide the optimal care for patients.

In this video, Peter Black, MD, of the University of British Columbia, Vancouver, Canada, speaks to us about the use of biomarkers to identify bladder cancer patients eligible for neoadjuvant therapy. Dr Black discusses three types of biomarkers currently under investigation, covering molecular subtypes, the COXEN model and alterations in specific DNA damage repair genes. This interview was recorded at the 2018 Genitourinary Cancers Symposium in San Francisco, CA.

Maria Teresa Bourlon, MD, MS, of Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, discusses the link between chemotherapy and premature ageing, via the biomarker p16INK4a, in testicular cancer survivors at the Genitourinary Cancers Symposium 2018, held in San Francisco, CA. Although testicular cancer patients can be cured successfully with chemotherapy, they still suffer from the long-term effects of the treatment. The results of Dr Bourlons research show an increased expression of the p16INK4a senescence protein in patients exposed to chemotherapy. p16INK4a has been found to inhibit CDK4/6 and promote p53 degradation, essentially causing premature senescence.…

Jeanny Aragon-Ching, MD, FACP, of Inova Schar Cancer Institute, Falls Church, VA, discusses the differences in survival rates of non-urothelial bladder cancer patients at the Genitourinary Cancers Symposium 2018, held in San Francisco, CA. Dr Aragon-Ching discusses how rare non-urothelial bladder cancers are, considering how non-urothelial neoplasms account for less than 5% of bladder neoplasms. Her group studied the SEER database and found that, of the different types of non-urothelial bladder cancers, adenocarcinomas had the best outcome. Contrastingly, research suggests squamous cell carcinomas have the poorest outcome. Dr Aragon-Ching emphasizes the need to develop clinical trials specifically targeting these rare…

Speaking at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Eugene Teoh, MBBS, MRCP, from the University of Oxford, Oxford, UK, introduces a pre-planned analysis of the FALCON trial (NCT02578940), which investigated the influence of 18F-fluciclovine PET/CT imaging for the management of prostate cancer patients considered for salvage curative therapy, following a first biochemical recurrence of the cancer. Dr Teoh discusses how the endpoint of the trial was determined by the percentage of patients with a change in their management plan. Results from the FALCON trial have shown promise, even in a population with low median prostate-specific antigen…

In this video, Elizabeth Plimack, MD, from Fox Chase Cancer Center, Philadelphia, PA, discusses the progress made in prostate, bladder and kidney cancer. There have been significant advances in immunotherapeutic options, particularly for the treatment of bladder and kidney cancers. Speaking from the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Dr Plimack mentions the challenges to overcome with non-responders and the different combinations that can be tested, particularly those including checkpoint inhibitors.

Dr. Jack West reviews general principles for how local therapies are increasingly appropriate for selected patients with advanced NSCLC, whether at initial management, for limited progression on systemic therapy, or as local consolidation therapy.

Silvia Novello, MD, PhD, of San Luigi Gonzaga University Hospital, Orbassano, Italy, discusses precision medicine at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland. She explains how precision medicine relies upon molecular testing, biomarkers, and drug availability, and that the key issue to tackle is making drugs more widely available for the purposes of precision medicine across Europe.

Dr. Dan Goldstein reviews results of a trial of chemo regimen TIP (paclitaxel, ifosfamide, cisplatin) vs BEP (bleomycin, etoposide, cisplatin) for intermediate/poor risk germ cell tumors, with discussion of outcomes in patients with a p53 mutation.

Speaking from the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Silvia Novello, MD, PhD, of San Luigi Gonzaga University Hospital, Orbassano, Italy, discusses the logistical implications of implementing tyrosine kinase inhibitor (TKI) treatments across different European countries. She highlights the differences in screening and treatment policies between countries, and explains how to improve these discrepancies in the future.

In this video, recorded at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Nicolas Girard, MD, PhD, of Claude Bernard University, Lyon, France, discusses treatment sequencing for EGFR mutant non-small cell lung cancer (NSCLC). He speaks about the wide range of TKIs and immune checkpoint inhibitors available, and how new research and clinical understanding will illuminate the best way to use these therapies in relation to other treatments such as chemotherapy.

In this video, recorded at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Silvia Novello, MD, PhD, of San Luigi Gonzaga University Hospital, Orbassano, Italy, discusses how to optimize the treatment of ALK+ non-small cell lung cancer (NSCLC), with a special focus on how practitioners from different European countries may have to approach this problem differently. She touches on policy, drug availability, and certain clinical considerations which might alter the ideal treatment plan.

Silvia Novello, MD, PhD, of San Luigi Gonzaga University Hospital, Orbassano, Italy, discusses results from recent clinical trials exploring the efficacy of different tyrosine kinase inhibitors (TKIs) on ALK-rearranged non-small cell lung cancer (NSCLC) at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland.

Several generations of tyrosine kinase inhibitors (TKIs) have now been produced and examined for the treatment of EGFR mutant non-small cell lung cancer (NSCLC). Here, Nicolas Girard, MD, PhD, of Claude Bernard University, Lyon, France, discusses the different TKI treatment options at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland. He explores the varied benefits of gefitinib, erlotinib, afatinib and osimertinib, as well as the results of the FLAURA trial (NCT02296125), and the implications of these data on treatment sequencing.

Here, Khaled Ghanem, MD, from the American University of Beirut, Beirut, Lebanon, outlines the collaborative approach taken by his institution, local government and non-profit organisations to help deliver stem cell transplant therapy for patients with thalassemia. Dr Ghanem was speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal.

In this video, Khaled Ghanem, MD, from the American University of Beirut, Beirut, Lebanon, encourages the use of social media, particularly Twitter, in order to facilitate communication between healthcare professionals. Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Dr Ghanem outlines the advantages of social media, including being able to receive updates from key congresses such as the American Society of Hematology (ASH) Annual Meeting & Exposition despite not being able to attend.

Here, Josep-Maria Ribera, MD, PhD, of Germans Trias i Pujol University Hospital, Barcelona, Spain, discusses the potential of measurable residual disease (MRD) testing to determine treatment outcome in acute leukemias. From the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Prof. Ribera describes the treatment options for patients who are MRD positive, including immunotherapy and stem cell transplantation, and the ideal times for MRD testing during the treatment pathway.

Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Khaled Ghanem, MD, from the American University of Beirut, Beirut, Lebanon, describes his experience of utilizing social media from a professional aspect in order to advance career development. Dr Ghanem points to the EBMTs dedication in supporting young physicians, having launched the EBMT Young Ambassador Program last year.

In this interview, Keith Kerr, MB, ChB, FRCPath, FRCPE, from the University of Aberdeen, Aberdeen, UK, makes predictions on what important changes are likely to take place in the field of lung cancer testing within the next year, particularly focusing on changes in molecular testing regulation and the development of new molecular tests. This video was recorded at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland.

An improved understanding of the disease biology of leukemia has driven personalized therapy that has helped lower the risk of relapse in patients. Here, Patrick Kiel, PharmD, BCOP, BCPS, of Indiana University Simon Cancer Center, Indianapolis, IN, discusses a case study in which the patient was identified with PD-L1 expression and a BRAF V600E mutation, and how these identifications helped improve the treatment outcome. Dr Kiel was speaking at the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO.

Speaking from the 2018 European Lung Cancer Congress (ELCC) in Geneva, Switzerland, Dean Fennell, PhD, FRCP, of the University of Leicester, Leicester, UK, stresses the need for increased randomized controlled trials (RCTs) looking at immunotherapies for treating mesothelioma, to establish its efficacy for cost-benefit analysis. Prof. Fennell also talks about the potential of gene knockout, particularly of the BAP1 gene.

In this video, Dean Fennell, PhD, FRCP, of the University of Leicester, Leicester, UK, talks about delivering personalized therapy for patients with thoracic malignancies. From the 2018 European Lung Cancer Congress (ELCC) in Geneva, Switzerland, Prof. Fennell outlines potential targets such as EGFR, ALK and PD-L1 expression, and how developing tailored therapy can improve the outcomes of relapsed patients.

In this video, Dean Fennell, PhD, FRCP, of the University of Leicester, Leicester, UK, discusses upcoming therapeutic targets for mesothelioma and sarcomatoid carcinoma. Speaking at the 2018 European Lung Cancer Congress (ELCC) in Geneva, Switzerland, Prof. Fennell talks about the drugs bevacizumab and nintedanib for targeting angiogenesis, immunotherapeutic treatments including nivolumab, pembrolizumab and ipilimumab, and also potential targets for genetic therapy such as the ASS1 protein and the BAP1 gene.

The human papilloma virus (HPV) currently has no cure, with virtually all cases of cervical cancer being caused by HPV. Here, Judith Smith, PharmD, BCOP, CPHQ, FCCP, FISOPP, of UTHealth McGovern Medical School, Houston, TX, discusses her findings looking at the nutritional supplement active hexose correlated compound, more commonly known as AHCC, that has shown promise in eradicating HPV. Dr Smith was speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO.       immune modulating, persistent high risk hpv, human papillomavirus, immune system, hpv infection, supplement ahcc, hpv infection in women

From the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Patrick Kiel, PharmD, BCOP, BCPS, of Indiana University Simon Cancer Center, Indianapolis, IN, delivers the case for collaboration between pharmacists and how HOPA can be used as a teaching platform to inform healthcare professionals of the latest techniques, such as next-generation sequencing (NGS).

In this video, Judith Smith, PharmD, BCOP, CPHQ, FCCP, FISOPP, of UTHealth McGovern Medical School, Houston, TX, delivers advice to pharmacists who wish to begin a career in clinical research. Speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Dr Smith stresses the importance of having a passion for undertaking research to overcome the challenges faced when going down this career path.

In this video, Patrick Kiel, PharmD, BCOP, BCPS, of Indiana University Simon Cancer Center, Indianapolis, IN, describes how identifying molecular aberrations can help personalize therapy for patients with certain cancers. Speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Dr Kiel stresses the need for more clinical trials to bring about further clinical advancements.

The importance of the clinical pharmacy specialist is often understated. Here, Judith Smith, PharmD, BCOP, CPHQ, FCCP, FISOPP, of UTHealth McGovern Medical School, Houston, TX, describes how these specialists play a key role in improving patient outcomes through advancing clinical research in areas such as quality improvement research. Dr Smith was speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO.

Speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Judith Smith, PharmD, BCOP, CPHQ, FCCP, FISOPP, of UTHealth McGovern Medical School, Houston, TX, discusses the importance of interweaving pharmacy research within clinical practice, and the role that HOPA plays in encouraging engagement and collaboration within pharmacy research in order to improve drug administration.

Richard Stone, MD, of the Dana-Farber Cancer Institute, Boston, MA, talks about the latest advances that have been made in acute myeloid leukemia (AML), including recent drug approvals after numerous years of testing and our increasing understanding of the pathophysiology of this disease. This interview took place at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting, in Lisbon, Portugal.

Fermin Sanchez-Guijo, MD, PhD, of Hospital Clínico Universitario de Salamanca, Salmanca, Spain, speaks to us about the role of mesenchymal stem cells in hematopoietic progenitor cell engraftment and the associated risks with this treatment, namely GvHD. This interview was recorded at the 2018 European Group for Blood and Marrow Transplantation (EBMT) Annual Meeting, held in Lisbon, Portugal.

Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Ernst Holler, MD, of University Hospital Regensberg, Regensberg, Germany, briefly outlines the mechanisms behind GvHD, before describing research currently being undertaken to decrease the risk of this condition developing and improve its management.

Anti-thymocyte globulin (ATG) is immunosuppressive antibody that has been around for >30 years, which is used to prevent graft-versus-host disease (GvHD) and the rejection of transplanted tissue. In this interview, Jaap Jan Boelens, MD, PhD, from UMC Utrecht, Utrecht, Netherlands, speaks about the results of his study investigating the pharmacokinetic profile of ATG in 500 cancer patients that received stem cell transplantation. This video was recorded at the 2018 European Group for Blood and Marrow Transplantation (EBMT) Annual Meeting, held in Lisbon, Portugal.

Speaking from the 2018 European Group for Blood and Marrow Transplantation (EBMT) Annual Meeting, held in Lisbon, Portugal, Genovefa Papanicolaou, MD, from Memorial Sloan Kettering Cancer Center, New York, NY, speaks about novel vaccines that are being developed for the treatment of cytomegalovirus (CMV) in cancer patients receiving stem cell transplants.

Martin Hutchings, MD, PhD from Copenhagen University Hospital, Copenhagen, Denmark, discusses current first-line treatment options in Hodgkin lymphoma at the European Blood and Marrow (EBMT) 2018 Annual Meeting, held in Lisbon, Portugal. He also speaks about novel agent therapies, and their potential for changing the treatment landscape in the future.

In this video, recorded at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Denis Claude Roy, MD, FRCP, of the University of Montreal, Montreal, Canada, discusses the practicality of implementing his technique for eradicating GvHD after haploidentical stem cell transplant by selectively killing active donor T-cells. This technique would be easily translated to an everyday clinical setting, as Dr Roy explains.

Denis Claude Roy, MD, FRCP, of the University of Montreal, Montreal, Canada, is involved in developing a technique for eradicating the risk of GvHD in haploidentical stem cell transplant recipients by selectively killing the donor cells that react to host cells. In this video, recorded at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, he discusses the wide-reaching potential for this technology, as well as considerations for donor matching.

Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Denis Claude Roy, MD, FRCP, of the University of Montreal, Montreal, Canada, discusses an innovative new photodynamic technique that eliminates the activated T-cells which can cause GvHD in haploidentical stem cell transplant recipients. This process has potential applications across a huge range of hematological malignancies.

Antonio Almeida, MD, PhD, of the Instituto Português de Oncologia Francisco Gentil, Lisbon, Portugal, gives an overview of acute myeloid leukemia (AML) pathophysiology at the European Society for Blood and Marrow Transplantation (EBMT) 2018 Annual Meeting, held in Lisbon, Portugal.

Speaking from the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Matti Aapro, MD, of the Clinique de Genolier, Genolier, Switzerland, discusses the hot topics in lung cancer today. He speaks about lung cancer screening, improved surgical techniques, and the increasing precision and efficacy of radiotherapy.

New lung cancer therapies are constantly being developed and approved. Indeed, the new treatments on the market have rendered chemotherapy increasingly redundant. Matti Aapro, MD, of the Clinique de Genolier, Genolier, Switzerland, spoke to us about this exciting new treatment landscape at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland. He discusses TKIs, immunotherapy, and the importance of continued adherence to guidelines and good scientific practice in the face of so many potential treatments.

Decreasing tobacco intake is a key goal for reducing the incidence of lung cancer. In this video, recorded at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Matti Aapro, MD, of the Clinique de Genolier, Genolier, Switzerland, discusses new initiatives being implemented by the Union for International Cancer Control (UICC) to decrease tobacco usage. The key incentive involves increasing cigarette prices, which has been shown to be highly effective; however, Dr Aapro also highlights the fact that in certain countries, such as China, a greater effort is required to effectively reduce smoking.

With the approval of new therapies that are restricted based on PD-L1 expression, there are many different assays to test for this. In this interview, Keith Kerr, MB, ChB, FRCPath, FRCPE, from the University of Aberdeen, Aberdeen, UK, discusses whether these tests are equivalent in terms the patients that are selected to receive the therapy and whether their clinical outcomes are the same. This interview was conducted at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland.

Lung cancer screening is an exciting and debated topic. Here, Mamta Ruparel, MBBS, MRCP, of University College London, London, UK, discusses the current data and logistical considerations associated with lung cancer screening at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland.

Mamta Ruparel, MBBS, MRCP, of University College London, London, UK, discusses the current data and guidelines associated with the finding of pulmonary nodules in lung cancer screening. She explains the relevance of this topic in the clinical setting, and suggests ways to improve the techniques used. This video was recorded at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland.

In recent years, there has been a massive increase in the number of different immunotherapeutic agents that can be used in the treatment of cancer. In this interview, Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, discusses why it is important that patients are only receiving the most appropriate therapy for their specific form of cancer, in terms of side-effects and the high cost of many of these drugs. This interview was conducted at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland.

Speaking from the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, provides an overview of recent trial data concerning the immunotherapy of non-oncogene addicted non-small cell lung cancer (NSCLC). Dr Scagliotti emphasizes the importance of exploring combinations of immunotherapy and other treatment modalities in a clinical setting.

Speaking from the 2018 European Lung Cancer Congress (ELCC) in Geneva, Switzerland, Federico Capuzzo, MD, PhD, of AUSL della Romagna, Ravenna, Italy, talks about how overall survival has improved in patients with non-small cell lung cancer (NSCLC) and the problems associated with this increase in survival.

In this interview, Federico Capuzzo, MD, PhD, of AUSL della Romagna, Ravenna, Italy, discusses novel therapies for the treatment of non-small cell lung cancer (NSCLC) from the 2018 European Lung Cancer Congress (ELCC) in Geneva, Switzerland. Dr Capuzzo focuses on immunotherapy and targeted agents, and emphasizes the continued importance of defining the biological characteristics of NSCLC, particularly PD-L1 expression.

Many infections can occur in cancer patients who are immunocompromised after receiving a stem cell transplant. In this interview, Genovefa Papanicolaou, MD, from Memorial Sloan Kettering Cancer Center, New York, NY, speaks about the current and future developments in the treatment of a particularly dangerous viral infection, cytomegalovirus (CMV). This interview was conducted at the 2018 European Group for Blood and Marrow Transplantation (EBMT) Annual Meeting, held in Lisbon, Portugal.

In this interview, Keith Kerr, MB, ChB, FRCPath, FRCPE, from the University of Aberdeen, Aberdeen, UK, makes predictions on what important changes are likely to take place in the field of lung cancer testing within the next year, particularly focusing on changes in molecular testing regulation and the development of new molecular tests. This video was recorded at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland.

Speaking from the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Keith Kerr, MB, ChB, FRCPath, FRCPE, from the University of Aberdeen, Aberdeen, UK, describes the increasing complexity of the role of pathologists in the field of lung cancer, with an increasing number of assays required for appropriate treatment selection.

Dr. Daniel Goldstein summarizes findings of a trial presented at ASCO 2018 by Dr. Kellolumpu-Lehtinen, assessing the benefit of adjuvant docetaxel for patients after radiation for patients with high or intermediate risk localized prostate cancer.

Dr. Daniel Goldstein reviews data on the positive predictive value of PET PSMA imaging in patients with biochemically relapsed prostate cancer, as presented by Wolfgang Fendler & colleagues at ASCO 2018.

Dr. Daniel Goldstein considers new data by Clarke & colleagues on a combination of the PARP inhibitor olaparib with abiraterone for molecularly unselected metastatic prostate cancer, along with providing a context of results from similar prior research.

BMIC058

In this video, Robin Foà, MD, from the University of Rome, Rome, Italy, discusses the impact of age on patients with Ph+ or Ph-like acute lymphoblastic leukemia (ALL). This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

Oliver Ottmann, MD, FRCPath, of Cardiff University, Cardiff, UK, raises the issue of slow progression of clinical trials in acute lymphoblastic leukemia (ALL) and the factors that play a part. Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Prof. Ottmann alludes to the lack of funding that presents a particular challenge regarding this topic.

Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Oliver Ottmann, MD, FRCPath, of Cardiff University, Cardiff, UK, gives an overview of the potential of improved techniques for detecting measurable residual disease (MRD) in patients with acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML), including next-generation sequencing and digital droplet PCR.

Here, Robin Foà, MD, from the University of Rome, Rome, Italy, discusses the potential of a chemotherapy-free strategy for patients with acute lymphoblastic leukemia (ALL). Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Prof. Foà points to that fact patients have achieved remission, and even measurable residual disease (MRD) negativity.

Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Robin Foà, MD, from the University of Rome, Rome, Italy, talks about the clinical approach when treating patients with Ph+ or Ph-like acute lymphoblastic leukemia (ALL).

In this video, Oliver Ottmann, MD, FRCPath, of Cardiff University, Cardiff, UK, discusses the importance of allogeneic transplant in different populations of patients with Ph-positive acute lymphoblastic leukemia (ALL). From the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Prof. Ottmann also emphasizes the areas for improvement in measurable residual disease (MRD) testing.

Oliver Ottmann, MD, FRCPath, of Cardiff University, Cardiff, UK, points to the need for improving the methodology of measurable residual disease (MRD) testing in acute lymphoblastic leukemia (ALL). Prof. Ottmann outlines the key areas of research in leukemia his laboratory has currently been focusing on. This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

Prakash Satwani, MD, of Columbia University Medical Center, New York, NY, speaks to us about the true cost of bone marrow transplant ,and highlights potential alterations to the process and alternative options to increase the affordability of treatment. This interview was recorded at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal.

In this video, Daniel DeAngelo, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, talks about how novel immunotherapeutic options could reduce the high rate of refractory acute lymphoblastic leukemia (ALL) that has resulted from the use of multiple chemotherapeutic agents. Dr DeAngelo describes the aim to identify patients who are at high risk of relapse from standard therapy, and to incorporate immunotherapeutic options within their induction therapy. This video was recorded at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal.

Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Daniel DeAngelo, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, outlines the range of novel therapies on the horizon for treating relapsed/refractory acute lymphoblastic leukemia (ALL), including monoclonal antibody-drug conjugates and CAR T-cells.

John P. Fruehauf, MD, UC Irvine Health, Looks at Data from Combination Studies | ASCO 2019 Will Show The Role of New Combinations at MOASC 2018

Fa-Chyi Lee, MD, UC Irvine Health, talks about Adjuvant Chemotherapy for Rectal Cancer | Possibly Use Single-Agent Capecitabine at MOASC 2018

Edward L. Nelson, MD, UC Irvine Health talks about hoe RET Inhibitors May Be Approved this Year | Systems-Based Approach to Molecular Derangements at MOASC 2018

Yung Lyou, MD, UC Irvine Health, talks about Keynote 61 Trial | See if Pembrolizumab Can be Moved to the 2nd-line Setting at MOASC 2018

John P. Fruehauf, MD, UC Irvine Health, explains New Treatment for Melanoma is Working Everywhere | Working For Metastatic Disease in Brain and Body at MOASC 2018

Nataliya Mar, MD, UC Irvine Health, talks about Emerging New Agents for Urothelial Carcinoma | Immunotherapies in Metastatic Castration-Resistant Patients at MOASC 2018

John P. Fruehauf, MD, UC Irvine Health, Looks at Combinations of Therapies | Combine Targeted BRAF Agents with Immunotherapy at MOASC 2018

Fa-Chyi Lee, MD, UC Irvine Health, talks about a possible Better Approach in the Next 1-2 Years | For RAS or BRAF Mutated Colorectal Cancer at MOASC 2018

Edward L. Nelson, MD, UC Irvine Health talk about PI3-Kinase Inhibitors Do Not Work in Tumor Agnostic Way | Targeted Therapeutics Toward HER2 Do Not Always Work at MOASC 2018

John P. Fruehauf, MD, UC Irvine Health, explains Practice-Changing Impact of Presented Data | Durability to the Benefit of Immunotherapy at MOASC 2018

Rita Sanghvi Mehta, MD, UC Irvine Health, talks about Improving Survival in Stage 4 Breast Cancer | S0226 Showed That Patients Could Have Improved Survival at MOASC 2018.

John P. Fruehauf, MD, UC Irvine Health, explains What to do with Stage 3 Disease | Which is a Better Agent with BRAF or IO Therapy at MOASC 2018

Nataliya Mar, MD, UC Irvine Health, talks about Phase 1 Urothelial Carcinoma Data Presented | Combination Therapies in Renal Cell Carcinoma at MOASC 2018

Speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Christine Walko, PharmD, BCOP, FCCP, of the Moffitt Cancer Center, Tampa, FL, discusses the important roles that pharmacists could play in the personalized treatment of cancer patients, and why this is valuable for both patients and clinics.

In this interview, David DeRemer, PharmD, BCOP, FCCP, of the University of Florida, Gainesville, FL, discusses mid-career changes that pharmacists typically undergo, and the things that they can do to to help facilitate these career transitions. This interview was conducted at the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO.

In this interview, Christine Walko, PharmD, BCOP, FCCP, of the Moffitt Cancer Center, Tampa, FL, speaks about the Moffitt Cancer Centre and their patients. Dr Walko then describes how they implemented molecular testing at the center. This video was recorded at the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO.

Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Daniel Wolff, MD, PhD, of the University Hospital of Regensburg, Regensburg, Germany, talks about the developments that have been made in treating chronic GvHD and highlights areas for future progress.

Speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Meeting, held in Denver, CO, Jill Kolesar, PharmD, MS, BCPS, FCCP, of the University of Kentucky, Lexington, KY, explains the role of a molecular tumor board, a group of experts in all areas of medicine, including pharmacists, oncologists, geneticists and bioinformaticians.

Dr. Daniel Goldstein reviews data by Drs. Gulley & colleagues on PROSTVAC vaccine in metastatic prostate cancer & discusses the implications of trials that fail in phase III despite looking extremely favorable in phase II studies.

The European Medicines Agency have announced their recommendation to restrict the use of pembrolizumab and atezolizumab to the first-line treatment of urothelial cancer patients with high PD-L1 expression. Here, Thomas Powles, MBBS, MRCP, MD, from Barts Cancer Institute, London, UK, explains the reasoning behind this development, and shares his insights on why this is a positive movement towards more personalized treatment for patients. This interview was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.

The ABACUS trial (NCT02662309), an investigator-initiated Phase II study investigating the safety and efficacy of two cycles of neoadjuvant atezolizumab in T2-T4a transitional cell carcinoma of the bladder prior to cystectomy, has shown that PD-L1 expression plays an important role in the efficacy of this drug. Complete response rates were seen to increase to 40% in the PD-L1 positive subgroup compared to 16% in the biomarker negative population. In this interview, Thomas Powles, MBBS, MRCP, MD, from Barts Cancer Institute, London, UK, discusses these results at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL. The…

In this video, recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Ross Camidge, MD, PhD, of the University of Colorado, Denver, CO, gives his highlights from the conference. He discusses the novel agents he thinks show the most potential in the field of lung cancer, as well as some studies with poor outcomes.

In this video, recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Susan Peterson, PhD, of the MD Anderson Cancer Center, Houston, TX, outlines the key findings from her study exploring the effect of mobile and sensor vital monitoring for head and neck cancer patients undergoing radiotherapy (NCT02253238). She discusses the implications of using technology in this setting, and looks forward to suggest future directions for this research.

With the positive results from recent trials like SPARTAN (NCT01946204) and PROSPER (NCT02003924), it is likely that drugs typically associated with metastatic castration-resistant prostate cancer (mCRPC), such as enzalutamide and apalutamide, will be shifted forward in treatment strategies to be used in non-metastatic patients. Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Stephane Oudard, MD, PhD, of Georges Pompidou Hospital, Paris, France, discusses the implications such a change would have on the overall treatment landscape of prostate cancer, as well as the role of imaging in establishing treatment plans.

Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Ross Camidge, MD, PhD, of the University of Colorado, Denver, CO, gives an update on the Phase III ALEX trial (NCT02075840), which compared ALK inhibitors alectinib and crizotinib as first-line therapies for advanced non-small cell lung cancer (NSCLC). In addition to alectinib, Dr Camidge discusses the second-generation ALK inhibitors brigatinib, ensartinib and lorlatinib.

In this video, recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Robert Figlin, MD, of Cedars-Sinai Medical Center, Los Angeles, CA, discusses the importance of sequential therapies in kidney cancer treatment. Immunotherapies and targeted agents are both mentioned, along with advice for practitioners who do not specialize in kidney cancer.

Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Peter Fasching, MD, from University Hospital Erlangen, Erlangen, Germany, comments on the importance of the development of therapies that can overcome resistance to hormone therapy, so that the use of chemotherapy for the treatment of breast cancer can be minimized.

In this video, recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Susan Peterson, PhD, of the MD Anderson Cancer Center, Houston, TX, discusses her recent trial that used mobile and sensor technology to identify symptom burden and dehydration risk in head and neck cancer patients undergoing radiation treatment (NCT02253238).

After promising efficacy data from the TROPIC trial (NCT00417079), cabazitaxel was approved for use in metastatic castration-resistant prostate cancer (mCRPC) post-docitaxel therapy. Until now, however, safety data for this drug have been lacking, as Stephane Oudard, MD, PhD, of Georges Pompidou Hospital, Paris, France, explained at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL. In this interview, he discusses the retrospective FUJI study, which used real world data to show that cabazitaxel is not only effective, but also safe, in this setting. Prof. Oudard emphasizes the relevance of these results to daily clinical practice.

Ross Camidge, MD, PhD, of the University of Colorado, Denver, CO, discusses single target therapies in thoracic oncology and beyond at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL. He speaks about ROR-gamma, a master controller drug with the potential to revolutionize the treatment landscape.

Robert Figlin, MD, of Cedars-Sinai Medical Center, Los Angeles, CA, gives an update on the ADAPT trial (NCT01582672), which investigates autologous dendritic cell vaccine therapy plus the standard of care for advanced renal cell carcinoma (RCC), and compares these data to results from the CARMENA trial (NCT00930033). This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.Robert Figlin, MD, of Cedars-Sinai Medical Center, Los Angeles, CA, gives an update on the ADAPT trial (NCT01582672), which investigates autologous dendritic cell vaccine therapy plus the standard of care for advanced renal cell carcinoma (RCC),…

In this interview, Peter Fasching, MD, from University Hospital Erlangen, Erlangen, Germany, discusses the design and the initial safety results of the Phase III RIBECCA trial (NCT03096847) investigating the efficacy and safety of ribociclib with letrozole for HR+ metastatic or advanced breast cancer. Dr Fasching then compares their results with the previous MONALEESA-2 (NCT01958021) and MONALEESA-3 (NCT02422615) studies, which also focused on the use of ribociclib for breast cancer. This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.

Rita Sanghvi Mehta, MD, UC Irvine Health, talks about Avoiding Chemotherapy in Subset of Patients | TAILORx Uses Scoring Method – Oncotype DX at MOASC 2018.

Yung Lyou, MD, UC Irvine Health, talks about Weighing Judgment Before Giving Ramucirumab | Ramucirumab is Viable Choice After REACH-2 Results at MOASC 2018

Edward L. Nelson, MD, UC Irvine Health says to Enroll Patients in Umbrella or Basket Trials | PI3-kinase Did Not Pan Out in NCI-MATCH Trial at MOASC 2018

Drs Jared Weiss and Joshua Bauml discuss advances in treatment for head and neck cancer from ASCO 2018.

John P. Fruehauf, MD, UC Irvine Health, explains how 50% of Melanoma Patients Develop Brain Metastases | BRAF-MEK & Immunotherapy Help Brain Metastases at MOASC 2018

Drs Jared Weiss and Joshua Bauml discuss advances in treatment for head and neck cancer from ASCO 2018.

Nataliya Mar, MD, UC Irvine Health, talks about Erdafitinib & Enfortumab Reached FDA Drug Designation | Will be Available in Clinics Within a Few Years at MOASC 2018

Rita Sanghvi Mehta, MD, UC Irvine Health, talks about Cyclin-Dependent Kinases to Endocrine Therapy | Adding CDK-46 inhibitors to Frontline or 2nd-Line Setting at MOASC 2018.

Drs Jared Weiss and Joshua Bauml discuss advances in treatment for head and neck cancer from ASCO 2018.

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, discusses the use of measurable residual disease (MRD) in acute myeloid leukemia (AML). Prof. Craddock covers the utility of MRD in determining risk of relapse following induction therapy. This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

Alan Burnett, MD, FRCP, of Cardiff University, Cardiff, UK, discusses the use of measurable residual disease (MRD) in acute myeloid leukemia (AML). Prof. Burnett highlights its utility as an independent predictor of outcome and questions how much MRD could displace other risk scores, as well as it’s possible indication of chemosensitivity.

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, discusses the use of targeted vs. broader agents in acute myeloid leukemia (AML). This interview was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

Alan Burnett, MD, FRCP, of Cardiff University, Cardiff, UK, discusses the antibody-drug conjugate gemtuzumab ozogamicin for acute myeloid leukemia (AML). Prof. Burnett covers the history of this drug, the challenges faced and the future of this therapy. This interview was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, discusses novel therapies that can be given in acute myeloid leukemia (AML) post-transplant to reduce the risk of relapse.

In this interview, Mark Levis, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, speaks about TP53-mutated myelodysplastic syndromes (MDS) and the results of the Phase Ib/II clinical trial (NCT03072043) headed by the MDS Clinical Research Consortium, which showed promising response rates for the treatment of this condition with the mutant p53 activator APR-246 when given in combination with azacitidine. This interview was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, discusses how we can improve outcomes after transplant in acute myeloid leukemia (AML). Prof. Craddock touches upon a range of avenues, including measurable residual disease, the optimal conditioning regimen and novel therapies. This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

With the increased use of next-generation sequencing (NGS) to identify mutations in patient’s own cancer cells, the off-label usage of non-approved drugs is on the rise. In this interview, Federico Capuzzo, MD, PhD, of AUSL della Romagna, Ravenna, Italy, discusses the reasons why, and in what situations, his practice uses drugs off-label to treat lung cancer. This video was recorded in the 2018 European Lung Cancer Congress (ELCC), in Geneva, Switzerland.

Speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Ginah Nightingale, PharmD, BCOP, of Thomas Jefferson University, Philadelphia, PA, discusses the importance of identifying chemotherapy drugs that cause cognitive impairment, and ensuring that physicians are aware of and can deal with these conditions. Dr Nightingale then speaks about the different types of patients that should be screened for cognitive impairment and what role pharmacists play in this testing.

Ginah Nightingale, PharmD, BCOP, of Thomas Jefferson University, Philadelphia, PA, discusses why cognitive impairment as a result of chemotherapy is not screened for, as well as how this should be tested and its importance. This video was recorded at the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO.

There is increasing evidence to suggest that chemotherapy contributes to changes in cognition. In this interview, Ginah Nightingale, PharmD, BCOP, of Thomas Jefferson University, Philadelphia, PA, describes the pathways through which chemotherapy may contribute to deficits in cognition in patients. This interview was recorded at the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO.

In this interview, Amy Pick, PharmD, BCOP, of Creighton University, Omaha, NE, speaks about different types of stressors for mid-career healthcare professionals, and specifically about what she believes to be the main stressor: the inflexibility of the work-family interface. This video was recorded at the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference.

Speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference held in Denver, CO, Amy Pick, PharmD, BCOP, of Creighton University, Omaha, NE, speaks about mid-career challenges that healthcare professionals face. She particularly focuses on career burnout, why it is important and methods that can be used to overcome it.

The American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, presented exciting updates in urothelial carcinoma. Here, Arlene Siefker-Radtke, MD, of the MD Anderson Cancer Center, Houston, TX, discusses data for the antibody-drug conjugate enfortumab vedotin, which targets Nectin-4 (EV-101; NCT02091999).

VXM01 is an orally-administered vaccine that elicits a systemic T-cell response targeting VEGFR-2. Here, Wolfgang Wick, MD, from the German Cancer Research Center, Heidelberg, Germany, discusses the results of the latest clinical trial investigating the use of this vaccine in patients with progressive glioblastoma who have failed radiochemotherapy with temozolomide. Treated patients demonstrated a direct response to the vaccine, and adverse events were minimal. The next step in this trial involves the use of a checkpoint inhibitor to further increase the efficacy of the vaccine. This interview was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held…

Arlene Siefker-Radtke, MD, of the MD Anderson Cancer Center, Houston, TX, reviews treatment options for bladder cancer. She highlights how MVAC is still used today, with clinical trials failing to identify agents with improved activity over this therapy. New immune checkpoint inhibitors are producing durable response, but only a small fraction of patients respond to these drugs. Dr Siefker-Radtke eloquently provides her insight into the view that bladder cancer is comprised of multiple tumor types and predicts the future of urothelial carcinoma therapy. This interview was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago,…

Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Wolfgang Wick, MD, of the German Cancer Research Center, Heidelberg, Germany, discusses GAPVAC-101 (NCT02149225), the first-in-human trial of a highly personalized peptide vaccination for patients with newly diagnosed gliobastoma. The investigations have demonstrated that the Actively Personalized Vaccines (APVACS) vaccines are generally well tolerated, with only a few patients suffering adverse reactions, such as local dermal reactions to the immune stimulants and brain edema. Further investigations may lead to the development of new blueprints for trials in personalized medicine in the future.

Joseph Bubalo, PharmD, BCOP, BCPS, of Oregon Health and Science University Hospital, Portland, OR, speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual meeting, held in Denver, CO, talks about whether physician-assisted death could eventually evolve into unwarranted euthanasia in the United States.

Speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Meeting, in Denver, CO, Joseph Bubalo, PharmD, BCOP, BCPS, of Oregon Health and Science University Hospital, Portland, OR, talks about the introduction of physician-aided death in the United States, its current statistics and its future outlook.

Arlene Siefker-Radtke, MD, of the MD Anderson Cancer Center, Houston, TX, discusses the first results of the primary analysis of the Phase II BLC2001 study (NCT02365597) of erdafitinib in patients with metastatic or unresectable urothelial carcinoma with FGFR alterations. Notably, immune ‘cold’ patients were observed to respond well to erdafitinib. Dr Siefker-Radtke highlights interesting future directions for this research. This interview was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.

In this video, recorded at the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Meeting, in Denver, CO, Jeanne McCarthy-Kaiser, PharmD, BCOP, of the University of Washington, Seattle, WA, speaks to us about how pharmacists can help patients with problems outside of the clinic, such as easing the financial burden of treatment, and how educating a patient about their treatment will make them more likely to adhere to the regimen.

Speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Jeanne McCarthy-Kaiser, PharmD, BCOP, of the University of Washington Medical Center, Seattle, WA, outlines the many roles pharmacists play for patients undergoing transplants, particularly relating to their pre- and post-transplant drugs.

Dr. Daniel Goldstein reviews data in genitourinary oncology from ASCO 2018, including a study of higher dose or prolonged duration of radium-223 (Xofigo) compared to standard dosing for 6 months with this agent in patients with metastatic prostate cancer.

Dr. Daniel Goldstein summarizes key data in genitourinary oncology from ASCO 2018, including new results on pembrolizumab (Keytruda) for metastatic prostate cancer, asking whether it could find a place as treatment for a subset of these patients.

Yung Lyou, MD, UC Irvine Health, talks about Selecting Patients for Adjuvant Pancreatic Treatment | Determine Who Has Better Performance Status at MOASC 2018

Fa-Chyi Lee, MD, UC Irvine Health, talks about the Major Impact from HIPEC is Insurance Reimbursement | Insurance Companies Feel Impact of Approval Rejection at MOASC 2018

Edward L. Nelson, MD, UC Irvine Health explains Number of Molecular Targets Are Overwhelming Practitioners | Practitioners Must Know What is Supported by Literature & Field at MOASC 2018

John P. Fruehauf, MD, UC Irvine Health, explains New Agents for BRAF-MEK Inhibition | Binimetinib/Encorafenib at MOASC 2018

Nataliya Mar, MD, UC Irvine Health, Addressing Non-Clear Cell Histology | Did Not Come Across Any Trials at MOASC 2018

Rita Sanghvi Mehta, MD, UC Irvine Health, explains High-Dose Fulvestrant Vs. Loading Dose | Loading Dose Prevents Early Progressions at MOASC 2018.

Yung Lyou, MD, UC Irvine Health, talks PRODIGE 24 Showed FOLFIRINOX has Benefits | FOLFIRINOX was Compared to Single-Agent Gemcitabine at MOASC 2018

Edward L. Nelson, MD, UC Irvine Health explains Whether to ReBiopsy a Tumor | Give Practitioners Understanding of Modalities at MOASC 2018

Fa-Chyi Lee, MD, UC Irvine Health, talks about the Negative Results from HIPEC Study | Surgery May Still Have Role at MOASC 2018

John P. Fruehauf, MD, UC Irvine Health, explains KEYTRUDA & Role in Stage 4 Melanoma | Immunotherapy has Long-Term Benefits After Treatment at MOASC 2018

Nataliya Mar, MD, UC Irvine Health, shares her Urothelial Carcinoma Abstracts | Enfortumab, Erdafitinib were Effective Based on Data at MOASC 2018

Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Torsten Haferlach, MD, of MLL Munich Leukemia Laboratory, Munich, Germany states his opinions on CAR T-cell therapies for the treatment of acute lymphocytic leukemia (ALL) and the difficulties associated with this treatment in the present day.

In this interview, Torsten Haferlach, MD, of MLL Munich Leukemia Laboratory, Munich, Germany, reflects on the differences between the treatment of acute lymphoblastic leukemia (ALL) in clinical practice and in a clinical trial setting, and the issues physicians face in a clinical environment. Prof. Haferlach then provides advice to doctors on what information they should give ALL patients about their condition. This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

Elizabeth Macintyre, MD, PhD, of the Hôpital Necker-Enfants Malades, Paris, France, speaks about the advances made in leukemia diagnostics and therapeutics from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Torsten Haferlach, MD, of MLL Munich Leukemia Laboratory, Munich, Germany, states his opinions as to which stratifications are the most important to inform treatment decisions in the early treatment of acute lymphoblastic leukemia (ALL).

With the recent maturation of novel therapies for acute myeloid leukemia (AML), the field of AML therapeutics is rapidly progressing. In this interview, Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the recently approved small molecule and antibody-based therapies in this field, and the types of therapy that are likely to be approved in the future. This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

In this interview, Torsten Haferlach, MD, of MLL Munich Leukemia Laboratory, Munich, Germany, speaks about the difficulties in diagnosing and treating particular subsets of acute lymphoblastic leukemia (ALL); he explains that this is because there are a plethora of different genetic factors that influence the way in which patients should be treated. This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses exciting novel avenues for multiple myeloma (MM) therapy from the 1st European Myeloma Network (EMN) Meeting, in Turin, Italy. Dr Munshi covers BCMA-targeting CAR T-cells, venetoclax, induction regimens and measurable reisdual disease monitoring.

Philip McCarthy, MD, of Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses new strategies for clinical trial design in multiple myeloma (MM). Prof. McCarthy highlights measurable residual disease and covers the different techniques that can be used to determine this. This video was recorded at the 1st European Myeloma Network Meeting, in Turin, Italy.

Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses considerations in the treatment of high risk multiple myeloma (MM) from the 1st European Myeloma Network (EMN) Meeting, in Turin, Italy. He covers more agressive therapy options, as well as intergrating our increased knowledge of genomics to improve treatment.

Philip McCarthy, MD, of Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses two Phase III multiple myeloma (MM) transplantation studies that have been performed: EMN02 (NCT01208766) and BMT CTN 0702 (NCT01109004). Prof. McCarthy highlights how both studies had similar designs, but yielded different results. This video was recorded at the 1st European Myeloma Network Meeting, in Turin, Italy.

Monika Engelhardt, MD, of the University Medical Center Freiburg, Freiburg, Germany, speaking from the 1st European Myeloma Network (EMN) Meeting 2018, held in Turin, Italy, discusses the cost-effectiveness of multiple myeloma (MM) treatments. She speaks about the expense associated with combination therapies, and the differences in drug costs between countries.

Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses advances in the classification of high risk multiple myeloma (MM) from the 1st European Myeloma Network (EMN) Meeting, in Turin, Italy. He highlights improvements in our understanding of the biology of the disease, and how the resulting genetic knowledge impacts our stratification of aggresive MM.

Yung Lyou, MD, UC Irvine Health, talks about 3 Clinical Trials in Non-Colorectal GI Cancers | REACH-2, KEYNOTE-061, PRODIGE 24 trials at MOASC 2018

Rita Sanghvi Mehta, MD, UC Irvine Health, explains how Patients were Given Anastrozole + Fulvestrant | Some Patients Over-Represented in Combination Arm at MOASC 2018.

Fa-Chyi Lee, MD, UC Irvine Health, talks about the HIPEC Study Requires Further Evaluation | Closed United States Intergroup Study Should be Reopened at MOASC 2018

Edward L. Nelson, MD, UC Irvine Health explains Topics Covered in ASCO 2018 | Precision Medicine, Next-Gen Sequencing, Tumor Cells, etc at MOASC 2018

Exciting updates on obinutuzumab were presented at the 23rd congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden. Final analysis results from the CLL11 study (NCT01010061) were presented at the press briefing by Dr Valentin Goede, of the German CLL Study Group, Cologne, Germany. Dr Goede highlights the overall survival benefit of obinutuzumab plus chlorambucil over rituximab in patients with chronic lymphocytic leukemia (CLL) and comorbidities.

Dr Olivier Casasnovas, from the Department of Hematology, Dijon, France, gives an update on data from the Phase III AHL2011 study (NCT01358747). Dr Casanovas highlights the outstanding disease control results observed with a minimized BEACOPP exposure and toxicity in patients with advanced Hodgkin lymphoma. This video was recorded at the 23rd congress of the European Hematology Association (EHA) 2018 press briefing, held in Stockholm, Sweden.

Data from the exciting iNNOVATE study (NCT02165397) of ibrutinib plus rituximab for patients with Waldenströms macroglobulinemia (WM) were presented at the 23rd congress of the European Hematology Association (EHA) 2018 press briefing, held in Stockholm, Sweden. Watch Dr Meletios Dimopoulos, of the National and Kapodistrian University of Athens School of Medicine, Athens, Greece, discusses this groundbreaking study, which could result in a new standard of care for WM.

Great strides have been made in the management of sickle cell disease. Here, Maria Cappellini, of the University of Milan-Foundation IRCCS Policlinico Hospital, Milan, Italy, discusses the basics of sickle cell disease to where we are now. This video was recorded at the 23rd congress of the European Hematology Association (EHA) 2018 press briefing, held in Stockholm, Sweden.

“Dr Laurie Sehn, of the BC Cancer Agency, Vancouver, BC, Canada presents: ‘Answering the unmet need in one of the most common types of lymphoma: Its as simple as A-D-C’. Dr Sehn discusses the use of polatuzumab vedotin, an antibody-drug conjugate (ADC), for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Based on the trial results presented (NCT02257567), this ADC has been granted Breakthrough Therapy Designation by the US Food and Drug Administration and PRIME (PRIority MEdicines) designation by the European Medicines Agency for R/R DLBCL. This video was recorded at the 23rd congress of the European Hematology Association (EHA) 2018…

John Gribben, of Barts Cancer Institute, London, UK, discusses making CAR T-cells happen in Europe. This video was recorded at the 23rd congress of the European Hematology Association (EHA) 2018 press briefing, held in Stockholm, Sweden.

Dr Jing Pan, of Beijing Boren Hospital, Beijing, P.R. China, discusses a new anti-CD22 CAR T-cell immunotherapy for pediatric relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). Dr Pan explains how this exciting study evaluated humanized CD22-specific CAR T-cell therapy for patients who had failed multiple lines of treatment, including allo-HCT and CD19-targeted CAR T-cell therapy. He covers the promising results and highlights how this new therapy gives otherwise untreatable patients a new hope. This video was recorded at the 23rd congress of the European Hematology Association (EHA) 2018 press briefing, held in Stockholm, Sweden.

HARMONY is Europe’s largest public-private partnership for big data in hematology. Here, Jesús María Hernández Rivas, HARMONY Alliance Project Coordinator, from IBSAL, Spain, discuses the alliance and how big data enable better and faster treatment for patients with hematologic malignancies. This video was recorded at the 23rd congress of the European Hematology Association (EHA) 2018 press briefing, held in Stockholm, Sweden.

Speaking from the 23rd congress of the European Hematology Association (EHA) 2018 press briefing, held in Stockholm, Sweden, Dr Jesús Berdeja of the Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, gives an update on bb2121, a promising therapy for patients with heavily pre-treated relapsed/refractory multiple myeloma (MM).

Dr Franck Morschhauser, of Centre Hospitalier Universitaire Régional de Lille, Unité GRITA, Lille, France, discusses the question: is RELEVANCE relevant? He covers the results of the Phase III study (NCT01476787) of R2 vs R-chemo in first-line follicular lymphoma. This video was recorded at the 23rd congress of the European Hematology Association (EHA) 2018 press briefing, held in Stockholm, Sweden.

Speaking from the 23rd congress of the European Hematology Association (EHA) 2018 press briefing, held in Stockholm, Sweden, Dr Francesca Vinchi, of the Iron Research Program, New York Blood Center, NY, discusses the role of iron in inflammation in three conditions associated with an over-accumulation of iron; transfusion-dependent anemia, anemia treated with intravenous iron preparations, and sickle cell disease. Dr Vinchi shares the interesting and insightful results of this work.

Dr Fang Liu, of Chengdu Military General Hospital, Chengdu, Sichuan, P.R. China, discusses first-in-human CLL1-CD33 compound CAR T-cells as a two-pronged approach for the treatment of refractory acute myeloid leukemia (AML). This video was recorded at the 23rd congress of the European Hematology Association (EHA) 2018 press briefing, held in Stockholm, Sweden.

Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, discusses the importance of measurable residual disease (MRD). Dr Fonseca describes the results of a study that found that patients with multiple myeloma (MM) who were MRD-positive had a similar outcome regardless of the type of response observed.

Speaking from the American Society of Oncology (ASCO) 2018, held in Chicago, IL, Michael Mauro, MD, of Memorial Sloan Kettering Cancer Center, New York, NY, talks about the future uses of asciminib and other novel drugs currently being developed for chronic myeloid leukemia (CML), before mentioning his hopes for the future of this disease with regards to patient remission.

In this interview, Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, discusses how measurable residual disease (MRD) should be used in the treatment of multiple myeloma (MM), including how his practice uses MRD. This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.

Eunice Wang, MD, of Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses extending the use of hypomethylating agents from patients with high risk myelodysplastic syndromes (MDS) to individuals with lower risk MDS. Data suggests that ~80% of patients with non-transfusion dependent, low risk MDS have vastly improved response rates upon receiving attenuated 3-5 day courses of decitabine or hypomethylating agents. Thus, Prof. Wang speculates the necessity of waiting for clinically significant anemia and cytopenia prior to starting therapy. Importantly, she notes that conclusions are difficult to ascertain, as patients with low risk MDS often have positive outcomes and a long…

Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, discusses the exciting preliminary results of the CRB-401 trial (NCT02658929) investigating the efficacy and safety of anti-BCMA CAR T-cell therapy bb2121 in patients with relapsed/refractory multiple myeloma (MM). Dr Fonesca discusses the trial in terms of response rates and measurable residual disease (MRD) status, and poses that these results are likely to translate well into progression-free and overall survival.

The recent FDA approval of bosutinib makes it the fourth inhibitor for the frontline treatment of chronic myeloid leukemia (CML), as Michael Mauro, MD, of Memorial Sloan Kettering Cancer Center, New York, NY, tells us in this interview. Dr Mauro explains how bosutinib has a unique safety profile that makes it more desirable than other inhibitors, such as imatinib, and emphasizes its use as a safe, effective inhibitor for CML patients (BFORE; NCT02130557). This interview was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.

One of the major downsides to immunotherapy is its high cost. In this interview, Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, discusses whether it is cost-effective for patients to receive monoclonal antibody therapy. Dr Fonseca then states that pharmacoeconomic analyses are much more complex than most people consider. This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.

Tyrosine kinase inhibitors (TKIs) are some of the most successful drugs available for the treatment of a myriad hematological cancers. However, they are not perfect, as patients can relapse or develop refractory cancers. In this video, Michael Mauro, MD, of Memorial Sloan Kettering Cancer Center, New York, NY, outlines the development of a new TKI, asciminib, which has shown to be effective in patients with chronic myeloid leukemia (CML) resistant to two or more previous TKIs (NCT03106779). Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Dr Mauro mentions the aims for the third…

The treatment of multiple myeloma (MM) can be very costly. Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, discusses whether patients are able to afford medication for MM, whether they face any financial problems, and finally if MM drugs are worth their cost.

There has been an influx of novel therapies within the field of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Here, Eunice Wang, MD, of Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses exciting developments in IDH inhibitors for these diseases, including the FDA-approved IDH2 inhibitor enasidenib for use relapsed/refractory IDH2-mutated AML. Furthermore, she explores advancements in the use of the IDH1 inhibitor ivosidenib, a well tolerated agent with response rates of ~40% and complete remission rates of 20%. She holds the hope that we can add these options to our treatment repertoire to improve patient outcomes. This interview was…

Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, discusses the situations in which measurable residual disease (MRD) should and should not be used to define the success of therapy. This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.

Dr. Daniel Goldstein reviews data from ASCO 2018 on patient-reported quality of life on atezolizumab/bevacizumab compared to sunitinib in metastatic kidney cancer, along with the context of other treatment options in this setting.

John P. Fruehauf, MD, UC Irvine Health, Axillary Dissection in Stage 2 or 3 Melanoma | No Benefit from Taking Lymph Nodes Out

Nataliya Mar, MD, UC Irvine Health, shares her Abstracts were Metastatic Genitourinary Malignancies | Mix of Urothelial Carcinoma, Prostate Cancer, & RCC at MOASC 2018

Rita Sanghvi Mehta, MD, UC Irvine Health, talks about SWOG S0226 – for Metastatic Breast Cancer | Addition of Fulvestrant and Anastrozole Improves Progression-Free and Overall Survival at MOASC 2018.

Nicola Giuliani, MD, PhD, from the University of Parma, Parma, Italy, talks about the clinical approach required when identifying and treating patients with smoldering myeloma. Dr Giuliani was speaking at the 1st European Myeloma Network (EMN) Meeting, held in Turin, Italy.

Speaking at the 1st European Myeloma Network (EMN) Meeting, held in Turin, Italy, Nicola Giuliani, MD, PhD, from the University of Parma, Parma, Italy, outlines the therapeutic options for patients with smoldering myeloma. While there is no indication to treat monoclonal gammopathy of undetermined significance (MGUS), a precursor to multiple myeloma (MM), smoldering myeloma patients eligible for autologous stem cell transplant can undergo three cycles of induction therapy followed by transplant, a regimen that has proven to improve progression-free and overall survival. For patients that are not eligible for transplant, such as those that are elderly, alternative therapies, including the…

The future of biology is becoming increasingly technologically-based. In this video, Dominique Bonnet, PhD, of the Francis Crick Institute, London, UK, begins by emphasizing the need for bioinformaticians in her own laboratory, as much of her research requires mathematical analysis, before continuing to speak about the applications of these new analytic methods in her current research, which involves tracking leukemic cell migration in murine models. Dr Bonnet mentions how stem cells are often overlooked when analyzing samples, as they do not always match the classical round, undifferentiated appearance, but instead have different morphologies, including filopodia, before concluding her interview by…

In this video, Dominique Bonnet, PhD, of the Francis Crick Institute, London, UK, outlines her group’s research into the biology of leukemia. Dr Bonnet explains how they overcame the limitations of studying human cells and disease in murine environments, and the many different applications that this technology can have once it’s fully developed. This interview was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

All types of healthcare, including measurable residual disease (MRD) testing should be available to everyone throughout Europe. Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, Elizabeth Macintyre, MD, PhD, of the Hôpital Necker-Enfants Malades, Paris, France, explains how groups such as EuroMRD Consortium are making this possible.

Measurable residual disease (MRD) testing is revolutionizing our ability to determine the disease state of a patient. In this video, Elizabeth Macintyre, MD, PhD, of the Hôpital Necker-Enfants Malades, Paris, France, speaks about the benefits of MRD and compares it to some alternative methods of screening. This interview took place at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias.

Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, Elizabeth Macintyre, MD, PhD, of the Hôpital Necker-Enfants Malades, Paris, France, explains why she believes typical B-cell lineage acute lymphoblastic leukemia (ALL) and T-cell ALL should be characterized as different diseases.

Felice Bombaci, from the AIL patient group for chronic myeloid leukemia (CML), Rome, Italy, discusses some important key topics in patient support in Italy for hematological malignancies. He speaks about the importance of using patient-reported outcomes in research, his efforts to design a survey to record these responses, and the need for increased awareness about the stigma faced by cancer patients. This video was recorded at the 1st European Myeloma Network (EMN) Meeting 2018, held in Turin, Italy.

Immunotherapy has been making rapid advancements as of late, especially the area of CAR T-cell therapy. Howard Burris, MD, FACP, FASCO, of the Sarah Cannon Research Institute, Nashville, TN, speaks about the promising outlook for CAR T-cells in the treatment of a variety of blood cancers, before discussing their potential applications in solid tumors. While these investigations are still in their early days, Dr Burris explains his hope that as technologies develop, so too will the area of personalized medicine. He concludes his interview by mentioning personalized cancer vaccines, vaccines tailor-made for the patient based on the genome of their…

Patients with metastatic Merkel cell carcinoma (MCC) that does not respond to chemotherapy have a very poor survival rate after 1-2 years, representing a great unmet need. Here, Paul Nghiem, MD, PhD, from the University of Washington, Seattle, WA, discusses the preliminary results of the Phase II JAVELIN Merkel 200 trial (NCT02155647) evaluating the efficacy and safety of avelumab for chemotherapy-refractory MCC. This interview was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.

In this video, James Gulley, MD, PhD, FACP, of the National Cancer Institute, Bethesda, MD, speaks about prostvac, a novel vaccine his research group is developing to combat prostate cancer. Dr Gulley outlines how prostvac works and describes the three arms of the PROSPECT Phase III trial (NCT01322490), before speaking about the preliminary results, which at first did not seem very conclusive, but, upon further analysis, did show a low level of efficacy. Dr Gulley then concludes his interview by referring to two patients who showed an incredible response to the drug, and what this means for its future. This…

Howard Burris, MD, FACP, FASCO, of the Sarah Cannon Research Institute, Nashville, TN, speaks to us about the different therapies being developed for the treatment of breast cancer. Dr Burris touches upon personalized medicine and how it is helping to determine the best course of treatment, before discussing new data from trials including TAILORx (NCT00310180) and PERSEPHONE (ISRCTN52968807). Dr Burris mentions the limitations currently posed by these new therapies, before concluding his interview by briefly mentioning the use of pembrolizumab and combination therapy in the treatment of non-small cell lung cancer. This interview was recorded at the American Society of…

Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Peter Schmid, MD, PhD, FRCP, from the Barts Cancer Institute, London, UK, discusses the results of their groundbreaking Phase II PAKT trial (NCT02423603) investigating the value of adding the AKT inhibitor capivasertib to paclitaxel for the first-line treatment of patients with metastatic triple-negative breast cancer (TNBC). Prof. Schmid talks about the changes in progression-free and overall survival observed in both the entire patient cohort and in a subset of patients with mutations that promote activation of the PI3K/AKT/mTOR pathway. He then compares these results with…

In this interview, Paul Nghiem, MD, PhD, from the University of Washington, Seattle, WA, discusses the results of the Phase II trial investigating pembrolizumab as a first-line treatment for advanced Merkel cell carcinoma (CITN-09; NCT02267603). Dr Nghiem compares the response rate and tolerability profile with that of chemotherapy, and then speaks about the shift in the treatment of Merkel cell carcinoma away from chemotherapy to immunotherapy. This interview was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.

In this video, James Gulley, MD, PhD, FACP, of the National Cancer Institute, Bethesda, MD, speaks to us about the development of M7824, a novel antibody capable of targeting PD-L1 and TGF-? simultaneously. Dr Gulley mentions the results obtained from preliminary trials of this drug and the subsequent studies his research group conducted (NCT02517398), all of which generated positive results, and briefly mentions one side effect that. while observed in many patients. was fairly harmless. Dr Gulley then speaks about the differential efficacy observed between HPV positive patients and those with HPV-associated cancers, before concluding his interview with a possible…

Cell-free (cf)DNA analysis is frequently used in lung cancer to identify therapeutic targets, but there has also been recent interest in using this technology to create a minimally invasive cancer screening methodology. In this video, recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Geoffrey Oxnard, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the Circulating Cell-free Genome Atlas study (CCGA; NCT02889978), which uses a combination of targeted sequencing, genome-wide sequencing and genome-wide methylation analysis to test whether cfDNA can be used to correctly identify which patients in a group of 12,000 are…

Dr. Daniel Goldstein discusses the results of a trial of first line pembrolizumab (Keytruda) as first line therapy for patients with metastatic clear cell renal cell carcinoma and the implications for the future role of immunotherapy in RCC.

Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Raúl Córdoba, MD, PhD, MS, of the Fundacion Jimenez Diaz University Hospital, Madrid, Spain, describes how it is likely that the treatment of lymphoma will shift towards chemotherapy-free approaches, which will be mostly based around CAR T-cell and other immunotherapies. Dr Córdoba then discusses clinical trial results that support this idea.

Paul Richardson, MD, from Dana-Farber Cancer Institute, Boston, MA, discusses the exciting results of the Phase III OPTIMISMM trial (NCT01734928) that he presented at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL. The aims of this trial were to investigate the tolerability and efficacy of the three-drug combination of pomalidomide, bortezomib and dexamethasone compared to the combination of bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma (MM) in patients who had previously received lenalidomide therapy. Prof. Richardson then speaks about the next steps to further improve this treatment regimen.

Patients with T-cell leukemias typically have a worse prognosis than those with B-cell malignancies. In this interview, Kimberly Dunsmore, MD, from Virginia Tech Carilion School of Medicine, Roanoke, VA, discusses the results of the COG AALL0434 trial (NCT00408005), which is the largest T-cell malignancy trial to date. The aims of this trial were to investigate whether it is safe to administer nelarabine to patients with T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia, and whether treating these patients with high-dose or escalating-dose methotrexate is more effective when they are given as part of complex chemotherapy protocols. Prof. Dunsmore lastly speaks…

Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Raúl Córdoba, MD, PhD, MS, of the Fundacion Jimenez Diaz University Hospital, Madrid, Spain, describes an innovative trial of elderly patients with malignancies that investigated the effect of patients reporting their symptoms and adverse events while receiving chemotherapy.

The CRB-401 trial (NCT02658929) aims to investigate the efficacy of bb2121 for multiple myeloma (MM) patients. In this interview, recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Howard Burris, MD, FACP, FASCO, of the Sarah Cannon Research Institute, Nashville, TN, outlines the preliminary results of the trial and speaks about the possible advances that could be made as a result.

In this interview, Raúl Córdoba, MD, PhD, MS, of the Fundacion Jimenez Diaz University Hospital, Madrid, Spain, discusses the problems facing clinicians in the treatment of elderly patients with lymphoma. Dr Córdoba then describes ways to improve patient treatment, including stratification based on their fitness and the use of different treatment modalities, such as CAR T-cell and other immunotherapeutic approaches. This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.

Julia Snider, PhD, from Precision Health Economics, San Francisco, CA, talks to us about the social value of the CAR T-cell product tisagenlecleucel for the treatment of relapsed or refractory pedatric acute lymphoblastic leukemia (ALL) in the United States. Dr Snider discusses the various social and economical factors that were analyzed as part of the study, commenting on the novel strategies that have been considered in order to managed these costs, as well as the consequence of treatment delays in ALL. This interview was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.

Precision, or personalized, medicine has often been regarded as the future of cancer treatment. In this interview, Howard Burris, MD, FACP, FASCO, of the Sarah Cannon Research Institute, Nashville, TN, outlines the many benefits and uses of precision medicine, ranging from dissecting the biology of metastatic tumors to accumulating information for clinical trials. Dr Burris explains why he advocates for methods such as next-generation sequencing rather than PET scans and other less informative tests, and mentions some of the types of cancers that are already being investigated using this new precision medicine approach. This interview was recorded at the American…